Lead Product(s): FL-118-based Drug Conjugate
Therapeutic Area: Oncology Product Name: FL-118
Highest Development Status: Discovery Product Type: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 03, 2021
The companies will combine Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $475.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 08, 2021
Pathios Therapeutics will team up with researchers at The University of Oxford to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages.